Metronidazole Noridem (Metronidazole)

Metronidazole enters susceptible anaerobic organisms and is reduced to reactive nitro radicals. These radicals interact with microbial DNA, causing strand breaks and inhibiting nucleic acid synthesis, which ultimately leads to cell death while sparing most aerobic human cells.

The dosage of Metronidazole Noridem is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Only a qualified prescriber should set the exact regimen.

Safety data for Metronidazole Noridem in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Metronidazole Noridem, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic bacteria and certain protozoa, offering a rapid bactericidal effect. Compared with broad‑spectrum agents like clindamycin, metronidazole often has fewer drug‑interaction concerns but may cause distinct side effects such as a metallic taste and disulfiram‑like reactions with alcohol.

Metronidazole Noridem should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Ensure the vial or ampoule remains sealed until use and discard any product that appears discolored or contaminated.

Metronidazole Noridem is given intravenously by a healthcare professional. The solution is typically diluted in an appropriate compatible fluid and infused over a prescribed period, following aseptic technique and institutional infusion guidelines.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions such as Stevens‑Johnson syndrome, hepatic toxicity, and neutropenia. Patients should be monitored for neurological symptoms, skin changes, liver function abnormalities, and blood count alterations during therapy.

Metronidazole Noridem is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. It should also be avoided in patients who cannot abstain from alcohol during treatment due to the risk of a disulfiram‑like reaction.